FHLC vs RSPH: Differences, Returns & Fees
Over the year to Nov 18, 2026, FHLC returned +19.8% to RSPH's +29.7%; 49% of their weight is in the same names.
- Return gap
- +9.9 pts1 year to Nov 18, 2026: RSPH ahead, total return
- Fee gap
- 0.32 ptsA year: FHLC 0.08%, RSPH 0.40%, per filings dated Nov 24, 2025 and Aug 27, 2026
- Overlap
- 49%Share of the two books held in common, holdings dated Jul 31, 2026 and Nov 17, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
FHLC +19.8%, RSPH +29.7%: RSPH +9.9 pts ahead, 1 year, Nov 18, 2025 to Nov 18, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in RSPH costs about $3.50 one way and $7.00 in and out, at a median spread of 0.07%. The 0.07% spread is RSPH’s 30-day median, from Invesco (fund page).
Fees over time
Hypothetical. $10,000 in RSPH for 10 years at 0.40% a year costs about $664 in fees and lost growth; FHLC at 0.08% would cost $135. Assumes 6% a year before fees, a sample rate, not a forecast.
Key numbers
FHLC costs 0.32 points a year less; their one-year returns differ by 9.9 points.
Pair scorecard
Open the table
| Total return, 1 year | +19.8% | +29.7% |
|---|---|---|
| Below its high | 4.8%, high on Nov 4, 2026 | 4.0%, high on Nov 4, 2026 |
| What it tracks | MSCI USA IMI Health Care 25/50 Index | S&P 500 Equal Weight Health Care Index |
| Expense ratio | 0.08% | 0.40% |
| Net assets, FHLC as of Oct 31, 2026 and RSPH as of Nov 17, 2026 | $4.0bn | $1.0bn |
| Holdings in common | 49% | |
| Top ten holdings, share of the fund | 51.9% | 19.3% |
The numbers behind it
Net assets: $4.0bn on Oct 31, 2026 for Fidelity MSCI Health Care Index ETF, and $1.0bn on Nov 17, 2026 for Invesco S&P 500 Equal Weight Health Care ETF.
Holdings in common uses holdings dated Jul 31, 2026 and Nov 17, 2026.
What they share
By the books each fund has filed, FHLC and RSPH hold 49% of their money in the same securities at the same weight. Holdings dated Jul 31, 2026 and Nov 17, 2026.
half
49% in common
Held in common
Show all 12 holdings
| Eli Lilly & Co | 13.35% | 1.88% |
| Intuitive Surgical Inc | 1.81% | 1.83% |
| Gilead Sciences Inc | 2.34% | 1.75% |
| Amgen Inc | 3.00% | 1.75% |
| AbbVie Inc | 6.42% | 1.75% |
| Thermo Fisher Scientific Inc | 3.09% | 1.70% |
| Danaher Corp | 1.80% | 1.66% |
| Stryker Corp | 1.62% | 1.73% |
| Medtronic PLC | 1.59% | 1.67% |
| Johnson & Johnson | 8.93% | 1.57% |
| Pfizer Inc | 2.06% | 1.56% |
| Vertex Pharmaceuticals Inc | 1.75% | 1.54% |
Only in FHLC
Show all 8 holdings
| Natera Inc | 0.52% |
| Revolution Medicines Inc | 0.44% |
| Alnylam Pharmaceuticals Inc | 0.39% |
| Royalty Pharma PLC | 0.35% |
| Tenet Healthcare Corp | 0.32% |
| Insmed Inc | 0.30% |
| United Therapeutics Corp | 0.30% |
| Guardant Health Inc | 0.28% |
Only in RSPH
Show all 2 holdings
| Invesco Government & Agency Portfolio | 0.03% |
| SECURITIES LENDING - BNYM | 0.00% |
Side by side
Open the table
| Fund | Fidelity MSCI Health Care Index ETF | Invesco S&P 500 Equal Weight Health Care ETF |
| Where it sits | Stock ETF | Stock ETF |
| Issuer | Fidelity | Invesco |
| What it is | Tracks an index | Tracks an index |
| Total return, 1 year | +19.8% | +29.7% |
| Its benchmark over the same days | +19.7% (VHT) | not measured |
| Gap to its benchmark | +0.1 pts vs VHT | not measured |
| Expense ratio | 0.08% | 0.40% |
| Already in the S&P 500 | 84.4% | 100.0% |
| Holdings | 334 | 63 |
| Net assets, FHLC as of Oct 31, 2026 and RSPH as of Nov 17, 2026 | $4.0bn | $1.0bn |
FHLC and RSPH on the fields both publish, as of Nov 18, 2026. Source: ETFIQ.
From Nov 2013 to Nov 2026, FHLC and RSPH returned about the same: +320.0% and +317.7%. FHLC swung slightly less: 16.6% to 17.3%. FHLC fell slightly less at its worst: −25.2% to −27.3%.
Full scorecard
Open the table
| Total return | +320.0% | +317.7% | Tie | Price change plus distributions, reinvested. |
| Annualized | +11.6% | +11.6% | Tie | Total return as a yearly rate. |
| Price return | +248.8% | +287.0% | RSPH | Price change alone, distributions left out. |
| Volatility | 16.6% | 17.3% | FHLC (slight) | Spread of weekly returns, annualized. Lower is steadier. |
| Downside deviation | 11.5% | 12.1% | FHLC (slight) | Like volatility, counting only weeks below the Treasury bill rate. |
| Max drawdown | −25.2% | −27.3% | FHLC (slight) | Deepest fall from a high to the low after it. |
| Sharpe | 0.63 | 0.61 | FHLC (slight) | Return above Treasury bills per unit of volatility. |
| Sortino | 0.91 | 0.87 | FHLC (slight) | Return above Treasury bills per unit of downside deviation. |
| Calmar | 0.46 | 0.42 | FHLC (slight) | Annualized return divided by the max drawdown. |
More
Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 679 weekly returns. Cash rate: the 13-week Treasury bill.
About FHLC
FHLC tracks an index. Over the year to Nov 18, 2026 it returned +19.8% with distributions reinvested, against +19.7% for its benchmark, the MSCI USA IMI Health Care 25/50 Index.
More
The prospectus expense ratio is 0.08% a year. By its holdings filed for Jul 31, 2026, 84% of the fund by weight is stocks the S&P 500 also holds, across 334 positions, with the top ten at 51.9%. It sat 4.8% below its high of Nov 4, 2026 on Nov 18, 2026.
About RSPH
RSPH tracks an index. Over the year to Nov 18, 2026 it returned +29.7% with distributions reinvested.
More
The prospectus expense ratio is 0.40% a year. By its holdings published by its issuer for Nov 17, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 63 positions, with the top ten at 19.3%. It sat 4.0% below its high of Nov 4, 2026 on Nov 18, 2026.
Questions people ask
Which returned more over the last year, FHLC or RSPH?
In the year to Nov 18, 2026, with distributions reinvested, FHLC returned +19.8% and RSPH +29.7%.
Which is cheaper, FHLC or RSPH?
FHLC is cheaper, by 0.32 percentage points a year. That is about $32 on $10,000 held for a year. Fees come from each fund's prospectus.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, FHLC against RSPH, data as of Nov 18, 2026. https://etfiq.com/compare/any/fhlc-vs-rsph
ETFIQ. (Nov 18, 2026). FHLC against RSPH. Retrieved from https://etfiq.com/compare/any/fhlc-vs-rsph
[FHLC against RSPH (ETFIQ, Nov 18, 2026)](https://etfiq.com/compare/any/fhlc-vs-rsph)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.